- Business EPS: Sanofi’s business EPS for 2Q is €1.73, beating the estimate of €1.64.
- Sales: Total sales reached €10.75 billion, surpassing the estimated €10.42 billion.
- Dupixent Sales: Net product sales for Dupixent were €3.30 billion, higher than the estimated €3.16 billion.
- Beyfortus Sales: Net sales amounted to €18 million, compared to the €14.5 million estimate.
- Aubagio Sales: Net sales hit €107 million, exceeding the estimated €88.4 million.
- Vaccines Sales: Total vaccines sales were €1.14 billion, beating the estimate of €1.1 billion.
- Influenza Vaccines Sales: Influenza vaccines sales were €115 million, surpassing the €97.8 million estimate.
- Biopharma Sales: Biopharma net sales were €9.44 billion, above the estimated €9.1 billion.
- Consumer Healthcare Sales: Sales grew by 6.6% year-over-year to €1.31 billion, slightly above the estimate of €1.29 billion.
- Constant Exchange Rates: Sales grew by 10.2% at constant exchange rates.
- Dupixent ex-FX Growth: Sales increased by 29.2% excluding foreign currency impacts.
- Aubagio ex-FX Decline: Sales dropped by 49.5% excluding foreign currency impacts.
- Vaccines ex-FX Decline: Sales fell by 4.8% excluding foreign currency impacts.
- Influenza Vaccines ex-FX Growth: Influenza vaccine sales grew by 20.2% excluding foreign currency impacts.
- Biopharma ex-FX Growth: Sales increased by 10.3% excluding foreign currency impacts.
- Consumer Healthcare ex-FX Growth: Sales rose by 9.6% excluding foreign currency impacts.
- Business Net Income: Reached €2.16 billion, above the estimate of €2.07 billion.
- Business Operating Income: Reached €2.81 billion, exceeding the estimate of €2.7 billion.
- Biopharma Operating Income: Achieved €2.57 billion, up 5.6% year-over-year, and exceeding the estimate of €2.4 billion.
- Consumer Healthcare Operating Income: Was €267 million, down 16% year-over-year, and below the €340.8 million estimate.
- Gross Margin: Gross margin was 74.2%, compared to 74.5% year-over-year and an estimate of 73.6%.
- Biopharma Gross Margin: Stood at 75.9%, compared to 75.8% year-over-year and an estimate of 76.1%
- Consumer Healthcare Gross Margin: Was 62.1%, compared to 65% year-over-year and an estimate of 65.2%.
- R&D Expenses: Reached €1.70 billion, an increase of 4.5% year-over-year, slightly below the estimate of €1.72 billion.
- Free Cash Flow: Generated €854 million in free cash flow.
- 2024 EPS Guidance: Sanofi expects 2024 business EPS to be stable at constant exchange rates, revising the previous guidance of a low single-digit percentage decrease.
- Consumer Healthcare Separation: The intended separation of Opella (Consumer Healthcare) is on track with the previously communicated timelines.
A look at Sanofi Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 4 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Sanofi, a prominent pharmaceutical company known for manufacturing prescription drugs and vaccines, has been assessed using the Smartkarma Smart Scores. These scores provide an overall outlook on different aspects of the company’s performance. Sanofi received a commendable score of 4 for both Dividend and Resilience, indicating strong performance in these areas. Additionally, the company achieved a score of 3 for both Value and Growth, suggesting a stable position with room for potential development. With a Momentum score of 4, Sanofi shows consistent and positive movement in the market. Overall, the Smart Scores reflect a favorable long-term outlook for Sanofi, positioning it well in the pharmaceutical industry.
Sanofi‘s operations as a pharmaceutical company include the production of a wide range of medicines such as those for cardiovascular issues, thrombosis, metabolic disorders, central nervous system conditions, and oncology. With a global reach, Sanofi caters to customers worldwide with its diverse portfolio of pharmaceutical products. The Smartkarma Smart Scores further reinforce Sanofi‘s positive outlook, particularly highlighting its strong dividend yield, resilience in challenging times, and promising growth potential. This assessment underscores Sanofi‘s position as a key player in the pharmaceutical sector, well-equipped to navigate future market dynamics.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
